Surufatinib with or without chemo for lung neuroendocrine tumors
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding chemotherapy to the drug surufatinib works better than surufatinib alone for people with a rare type of lung cancer called pulmonary neuroendocrine tumor. If you have this diagnosis and haven't had prior systemic treatment, you may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of pulmonary neuroendocrine tumor (typical or atypical carcinoid).
- You must have at least one tumor that can be measured on scans.
- You must not have received any previous systemic therapy for your cancer, except chemotherapy given before or after surgery if it was over 6 months ago.
- You must be in good general health (ECOG score 0 or 1; or 0–2 if you are an amputee).
- You must have adequate kidney, liver, and blood cell counts as determined by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted therapies (surufatinib and serplulimab) plus standard chemotherapy (platinum and etoposide) for people with a rare, aggressive type of cancer called neuroendocrine carcinoma that started outside the lung. The goal is to see if this new combination works better than chemotherapy alone.
This trial tests a combination of targeted therapy (Surufatinib) and chemotherapy (Temozolomide and S-1) as a first treatment for advanced neuroendocrine tumors that have not been treated before. It aims to see if this drug combo is safe and effective.
This trial tests the drug surufatinib in people with advanced neuroendocrine tumors. It is a real-world study, meaning it looks at how the drug works in everyday practice, and may help control tumor growth.
This trial tests a combination of two drugs (surufatinib and tislelizumab) for people with advanced lung cancer that has neuroendocrine markers. It may be an option if you haven't had certain prior treatments and your overall health is fairly good.
This trial tests a combination of targeted therapy (surufatinib), immunotherapy (serplulimab), and standard chemotherapy as a first treatment for advanced solid tumors that have neuroendocrine features. It aims to see if this combination can shrink tumors and improve outcomes for patients with certain cancers.
The purpose of this study is to see how well the medication surufatinib works and how safe it is for people with neuroendocrine tumours. They want to gather more information from a real-world setting to understand the benefits and side effects of this treatment.
Hear when a new Pulmonary Neuroendocrine Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.